CD274 and neoplasm: Immune checkpoint inhibitors (ICIs), such as anti-CTLA-4, anti-PD1 and anti-PD-L1 antibodies, interfere with the inhibitory pathways of T-cell reactivity, overcoming tumor escape and activating T-cell effector function [170].